- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04518293
Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension (GMRx2_ACT)
Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Dual Combinations for the Treatment of Hypertension
Study Overview
Status
Conditions
Intervention / Treatment
- Drug: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
- Drug: telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
- Drug: Telmisartan 20 mg/amlodipine 2.5 mg .
- Drug: telmisartan 40 mg/amlodipine 5 mg
- Drug: Telmisartan 20 mg/indapamide 1.25 mg
- Drug: telmisartan 40 mg/indapamide 2.5 mg
- Drug: Amlodipine 2.5 mg/indapamide 1.25 mg
- Drug: amlodipine 5 mg/indapamide 2.5 mg
Detailed Description
TRIAL DRUG:
GMRx2: Single pill combinations of telmisartan/amlodipine/indapamide Dose version 2: telmisartan 20mg/amlodipine 2.5mg/indapamide 1.25mg Dose version 3: telmisartan 40mg/amlodipine 5 mg/indapamide 2.5mg INDICATION: Hypertension TRIAL DESIGN: International, multicenter, randomized, double-blind, active controlled, parallel-group.
OBJECTIVES: To investigate the efficacy and safety of GMRx2 compared to dual combinations
INTERVENTION:
Single-Blind Active Run-In Period. Enrolled participants will be asked to discontinue their current BP-lowering drug(s) and undergo a single-blind active run-in period for 4 weeks with GMRx2 dose version 2. Participants will be advised to take the capsule once daily in the morning at the same time (± 2 hours) before home BP measurement is performed.
Double-Blind Treatment Period. Participants still eligible after the run-in period will be allocated in a double-blind fashion to one of the following 4 randomized groups: GMRx2 dose version 2, or telmisartan20mg+amlodipine2.5mg, or telmisartan 20mg+indapamide 1.25mg, or amlodipine2.5mg+indapamide 1.25mg. At week 6 all doses will be doubled.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Suzanne Milne
- Phone Number: +19013900306
- Email: gmrx2gpm@georgeclinical.com
Study Contact Backup
- Name: Erin Corstanje
- Phone Number: M +44 (0)7879192633
- Email: ecorstanje@george-medicines.com
Study Locations
-
-
New South Wales
-
Castle Hill, New South Wales, Australia, 2154
- Castle Hill Medical Centre
-
-
Queensland
-
Brisbane, Queensland, Australia, 4102
- Princess Alexandra Hospital - Hypertension Unit
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Hudson Institute of Medical Research
-
Geelong, Victoria, Australia, 3220
- Barwon Health, Geelong University Hospital
-
-
Western Australia
-
Bentley, Western Australia, Australia, 6102
- Curtin University
-
Perth, Western Australia, Australia, 6000
- Royal Perth Hospital
-
-
-
-
Kralovehradsky
-
Broumov, Kralovehradsky, Czechia, 550 01
- EDUMED, s.r.o
-
Jaroměř, Kralovehradsky, Czechia, 551 01
- EDUMED, s.r.o
-
-
Stredocesky
-
Brandýs Nad Labem, Stredocesky, Czechia, 250 01
- Private Cardiologic Ambulance, Medicus Services s.r.o
-
-
-
-
-
Gisborne, New Zealand, 4040
- Gisborne Hospital
-
-
Auckland
-
Otahuhu, Auckland, New Zealand, 2025
- Middlemore Clinical Trials
-
-
-
-
-
Gdańsk, Poland
- Medical University of Gdansk
-
Katowice, Poland, 40-081
- Pratia Katowice Medical Centre
-
Katowice, Poland
- Pratia Katowice Medical Centre
-
Nowy Dwór Mazowiecki, Poland
- Nowodworskie Medical Center
-
Poznań, Poland
- Medical Center Pratia Poznan
-
Skierniewice, Poland, 96-100
- ETG Network
-
Skierniewice, Poland
- ETG Network
-
Warsaw, Poland
- The Medical University of Warsaw
-
Wrocław, Poland
- EMC Instytut Medyczny S.A
-
Wrocław, Poland
- Futuremeds
-
-
Gdansk
-
Gdańsk, Gdansk, Poland, 80-214
- Medical University of Gdansk
-
-
Wroclaw
-
Wrocław, Wroclaw, Poland, 50-088
- Futuremeds
-
-
-
-
-
Colombo, Sri Lanka, 10-01000
- Clinical Medicine Academic & Research Centre
-
Colombo, Sri Lanka, 10-01000
- Institute of Cardiology, National Hospital of Sri Lanka
-
Dehiwala, Sri Lanka, 10350
- Colombo South Teaching Hospital
-
Galle, Sri Lanka, 80000
- Karapitiya Teaching Hospital
-
Jaffna, Sri Lanka, 40000
- Jafna Teaching Hospital
-
Kandy, Sri Lanka, 20000
- Kandy National Hospital
-
Kurunegala, Sri Lanka, 60000
- Kurunegala Teaching Hospital
-
Negombo, Sri Lanka, 11500
- Negombo District General Hospital
-
Nugegoda, Sri Lanka, 10250
- Sri Jayawardenapura General Hospital
-
Ragama, Sri Lanka, 11010
- Colombo North Teaching Hospital
-
-
-
-
-
London, United Kingdom, EC1M6BO
- Bart's NHS Trust
-
Sheffield, United Kingdom, S35 9XQ
- Ecclesfield Group Practice
-
-
Cambridgeshire
-
Soham, Cambridgeshire, United Kingdom, CB7 5JD
- Steploe Medical Centre
-
-
Cheshire
-
Sandbach, Cheshire, United Kingdom, CW11 1EQ
- Ashfields Primary Care Centre
-
-
Cornwall
-
Newquay, Cornwall, United Kingdom, TR7 1RU
- Newquay Medical
-
-
Derbyshire
-
Chesterfield, Derbyshire, United Kingdom, S40 4AA
- Royal Primary Care Ashgate
-
-
Durham
-
Darlington, Durham, United Kingdom, DL3 8SQ
- Carmel Medical Practice
-
-
East Midlands
-
Leicester, East Midlands, United Kingdom, LE5 4PW
- PRC Leciester
-
-
Herts.
-
Hitchin, Herts., United Kingdom, SG49TH
- Portmill Surgery
-
-
Lancashire
-
Blackpool, Lancashire, United Kingdom, FY3 7EN
- Layton Medical Centre
-
Blackpool, Lancashire, United Kingdom, FY4 3AD
- Waterloo Medical Centre
-
-
Leicestershire
-
Hinckley, Leicestershire, United Kingdom, LE10 2SE
- Burbage Surgery
-
-
London
-
Harrow, London, United Kingdom, HA3 7LT
- Belmont Health Centre
-
-
Poole
-
Upton, Poole, United Kingdom, BH165PW
- The Adam Practice
-
-
Somerset
-
Bath, Somerset, United Kingdom, BA2 3HT
- Heart of Bath Medical Partnership
-
Bristol, Somerset, United Kingdom, BS37 4AX
- West Walk Surgery
-
Nailsea, Somerset, United Kingdom, BS48 1BZ
- Tyntesfield Medical Group
-
-
South Yorkshire
-
Rotherham, South Yorkshire, United Kingdom, S65 1DA
- Clifton Medical Centre
-
-
Wales
-
Cardiff, Wales, United Kingdom, CV32 4RA
- Ely Bridge
-
-
Warwickshire
-
Atherstone, Warwickshire, United Kingdom, CV9 1EU
- Atherstone Surgery
-
-
West Midlands
-
Coventry, West Midlands, United Kingdom, CV3 6NF
- Lakeside Surgery
-
Leamington Spa, West Midlands, United Kingdom, CV324RA
- Sherbourne Medical Centre
-
-
Wiltshire
-
Chippenham, Wiltshire, United Kingdom, SN15 2SB
- Rowden Surgery
-
Chippenham, Wiltshire, United Kingdom, SN14 6GT
- Hathaway Surgery
-
Trowbridge, Wiltshire, United Kingdom, BA14 8LW
- Trowbridge Health Centre
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85018
- Elite Clinical Studies
-
Scottsdale, Arizona, United States, 85260
- Headlands Research
-
Tucson, Arizona, United States, 85712
- Quality of Life Medical & Research Associates
-
-
California
-
S. Gate, California, United States, 90280
- Valiance Clinical Research
-
Tarzana, California, United States, 91356
- Valiance Clinical Research
-
-
Florida
-
Brandon, Florida, United States, 33511
- Clinical Research of Brandon
-
Hialeah, Florida, United States, 33013
- Inpatient Research Clinic
-
Lake City, Florida, United States, 32055
- Multi-Speciality Research Associates
-
Miami, Florida, United States, 33165
- New Horizon Research Center
-
Miami, Florida, United States, 33135
- Suncoast Research Group
-
Ocala, Florida, United States, 34471
- Ocala Research Institute
-
Saint Petersburg, Florida, United States, 33173
- Suncoast Research Associates
-
Saint Petersburg, Florida, United States, 33709
- Accel Research
-
Tampa, Florida, United States, 33603
- Precision Research Center
-
-
Georgia
-
Savannah, Georgia, United States, 31406
- Meridian Clinical Research
-
Snellville, Georgia, United States, 30078
- Buckhead Primary Care Research
-
-
Illinois
-
Maywood, Illinois, United States, 60153
- Loyola University
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Meridian Clinical Research
-
-
New York
-
Endwell, New York, United States, 13760
- Meridian Clinical Research
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28210
- Javarra Research
-
Greenville, North Carolina, United States, 27834
- East Carolina University
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- The University of Tennessee Health Science Center
-
-
Texas
-
Austin, Texas, United States, 78735
- ACRC Trials - Southwest Medical Village
-
Austin, Texas, United States, 78746
- ACRC Trials - Premier Family Physicians
-
Carlton, Texas, United States, 75010
- ACRC Trials - Family Medicine Associates of Texas
-
Houston, Texas, United States, 77036
- Synergy Groups Medical
-
Houston, Texas, United States, 77087
- Synergy Groups Medical
-
Missouri City, Texas, United States, 77459
- Synergy Groups Medical
-
North Richland Hills, Texas, United States, 76180
- North Hills Medical Research
-
Plano, Texas, United States, 75093
- ACRC Trials - Village Health Partners
-
-
Virginia
-
Portsmouth, Virginia, United States, 23703
- Meridian Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
At screening visit
- Provided signed consent to participate in the trial.
- Adult of age ≥18 years.
- Attended automated clinic seated mean SBP (average of last 2 measurements calculated by the device):
150-179 mmHg on 0 blood pressure (BP)-lowering drugs, or 140-170 mmHg on 1 BP-lowering drug, or 130-160 mmHg on 2 BP-lowering drugs, or 120-150 mmHg on 3 BP-lowering drugs.
At randomization visit
- Home seated mean SBP 110-154 mmHg in the week prior to the randomization visit .
- Adherence of 80-120% to run-in medication.
- Tolerated run-in medication.
- Adherence to home BP monitoring schedule: ≥3 days in the week before the randomization visit and ≥1 day per week during the preceding weeks, , with ≥2 measures in the specified morning and evening time periods on each day (i.e. accepting measures outside of the recommended 0600-1000 and 1800-2200 periods as long as they are in the am or pm, respectively).
At week 12 (for optional open-label extension)
- Provided signed informed consent.
- completed randomized treatment and willing to continue GMRx2-based regimen for up to 12 months.
Exclusion Criteria:
At screening visit
- Receiving 4 or more BP-lowering drugs.
- receiving any BP lowering drugs for indications other than hypertension e.g. heart failure
- Pregnant or had a positive pregnancy test or unwilling to undertake a pregnancy test during the trial and up to 30 days after the discontinuation of the trial medication or breastfeeding or of childbearing age and not using an acceptable method of contraception. Acceptable methods of birth control include hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (e.g. condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), or male partner sterilization. Contraception should be used for at least 1 month before the screening visit and until the end of trial participation.
- Not suitable for participation in a clinical trial according to local ethical or regulatory requirements related to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
- Contraindication, including hypersensitivity (e.g. anaphylaxis or angioedema), to the active run-in treatment or to any of the trial medication options in the four randomized groups.
- Current/history of transient ischemic attack, stroke, or hypertensive encephalopathy.
- Current/history of acute coronary syndrome, unstable angina, myocardial infarction, percutaneous transluminal coronary revascularization, or coronary artery bypass graft.
- Current atrial fibrillation. Patients with a history of paroxysmal atrial fibrillation are potentially eligible as long as there has been no episode in the last 3 months, while patient with a history of persistent or permanent atrial fibrillation are not eligible.
- Current/history of New York Heart Association class III and IV congestive heart failure.
- Current/history of a known secondary cause of hypertension, such as primary aldosteronism, renal artery stenosis, pheochromocytoma, or Cushing's syndrome.
- Current/history of substantially uncontrolled diabetes (HbA1c > 11.0%) within last three months.
- Current/history of end-stage renal disease or anuria or estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m2.
- Electrolyte levels that would be regarded as contraindications for any of the potential treatment arms e.g. serum sodium <132mmol/l or >148mmol/l serum potassium <3.1 mmol/l or >5.6 mmol/l.
- Current/history of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times the upper limit of normal range within 6 months.
- Current concomitant illness or physical impairment or mental condition that in the judgment of the investigator could interfere with the effective conduct of the trial or constitutes a significant risk to the participants' well-being.
- Arm circumference that is too large (>55 cm) or too small (<20 cm) to allow accurate measurement of BP.
- Currently taking or might need during the trial, a concomitant treatment which is known to interact with one or more of the trial medications: digoxin, lithium, diabetics receiving aliskiren, moderate and strong CYP3A4 inhibitors (e.g. ritonavir, ketoconazole, diltiazem], simvastatin >20 mg/day, immunosuppressants.
- Might need treatment with drugs that are prohibited during the trial: other antihypertensive drugs, endothelin receptor antagonists, neprilysin inhibitors, or other drugs that may affect BP (see Appendix 5).
- Current surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of trial drugs such as prior major gastrointestinal tract surgery (e.g. gastrectomy, lap band, or bowel resection) or acute flare of inflammatory bowel disease within one year.
- Individuals working >2 nightshifts per week.
- Participated in any investigative drug or device trial within the previous 30 days.
- History of alcohol or drug abuse within 12 months.
At randomization visit
- Unable to adhere to the trial procedures during the run-in treatment period.
Any of the following which in the investigator's judgment may compromise the safety of the participant if randomized to the trial medications:
- High or low clinic BP levels even in the light of the values for home BP that are available for that participant. The exact levels of BP are not specified, since there is clinical uncertainty as to the relevance of BP levels which are high or low in clinic only; for example, the clinical relevance of 'whitecoat hypertension' is uncertain.
- High or low home diastolic BP (DBP) levels. The exact levels of DBP is not specified, reflecting clinical uncertainty of the implications of isolated diastolic hypertension. However, home DBP values of >99 mmHg may typically be considered as requiring treatment intensification, and such participants would not be suitable for randomization.
- Any abnormal laboratory value which in the judgment of the investigator could interfere with the effective conduct of the trial or constitutes a significant risk to the participants' well-being.
- Fulfilling any of the exclusion criteria mentioned for the screening visit, when verified again at randomization visit.
At week 12 (for optional open-label extension)
1. contraindication to open-label GMRx2-ased BP-lowering treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Triple - TAI
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg.
At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
|
Single pill
Signle pill
|
Active Comparator: Dual - TA
Telmisartan 20 mg/amlodipine 2.5 mg .
At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg
|
oral tablet
oral tablet
|
Active Comparator: Dual - TI
Telmisartan 20 mg/indapamide 1.25 mg.
At week 6 visit, forced up-titration to telmisartan 40 mg/indapamide 2.5 mg
|
oral tablet
oral tablet
|
Active Comparator: Dual - AI
Amlodipine 2.5 mg/indapamide 1.25 mg.
At week 6 visit, forced up-titration to amlodipine 5 mg/indapamide 2.5 mg
|
oral tablet
oral tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in change in home SBP from baseline to week 12
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in change in clinic seated mean SBP from baseline to Week 12
Time Frame: 12 weeks
|
12 weeks
|
Difference in change in clinic seated mean SBP from baseline to Week 6
Time Frame: 6 weeks
|
6 weeks
|
Difference in change in clinic seated mean DBP from baseline to Week 12
Time Frame: 12 weeks
|
12 weeks
|
Difference in change in clinic seated mean DBP from baseline to Week 6
Time Frame: 6 weeks
|
6 weeks
|
Percentage of participants with clinic seated mean SBP <140 and DBP <90 mmHg at Week 12
Time Frame: 12 weeks
|
12 weeks
|
Percentage of participants with clinic seated mean SBP <140 and DBP <90 mmHg at Week 6
Time Frame: 6 weeks
|
6 weeks
|
Percentage of participants with clinic seated mean SBP <130 and DBP <80 mmHg at Week 12
Time Frame: 12 weeks
|
12 weeks
|
Percentage of participants with clinic seated mean SBP <130 and DBP <80 mmHg at Week 6
Time Frame: 6 weeks
|
6 weeks
|
Difference in change in home seated mean SBP from baseline to Week 6
Time Frame: 6 weeks
|
6 weeks
|
Difference in change in home seated mean DBP from baseline to Week 12
Time Frame: 12 weeks
|
12 weeks
|
Difference in change in home seated mean DBP from baseline to Week 6
Time Frame: 6 weeks
|
6 weeks
|
Difference in change in trough home seated mean SBP from baseline to week 12
Time Frame: 12 weeks
|
12 weeks
|
Difference in change in trough home seated mean SBP from baseline to Week 6
Time Frame: 6 weeks
|
6 weeks
|
Percentage of participants with home seated mean SBP <135 and DBP <85 mmHg at Week 12
Time Frame: 12 weeks
|
12 weeks
|
Percentage of participants with home seated mean SBP <135 and DBP <85 mmHg at Week 6
Time Frame: 6 weeks
|
6 weeks
|
Percentage of participants with home seated mean SBP <130 and DBP <80 mmHg at Week 12
Time Frame: 12 weeks
|
12 weeks
|
Percentage of participants with home seated mean SBP <130 and DBP <80 mmHg at Week 6
Time Frame: 6 weeks
|
6 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants discontinued trial medication due to AE/SAE from baseline to week 12
Time Frame: 12 weeks
|
Safety Outcomes
|
12 weeks
|
Percentage of participants discontinued trial medication due to AE/SAE from baseline to Week 6
Time Frame: 6 weeks
|
Safety Outcomes
|
6 weeks
|
Percentage of participants with an SAE from baseline to Week 12
Time Frame: 12 weeks
|
Safety Outcomes
|
12 weeks
|
Percentage of participants with SAE from baseline to Week 6
Time Frame: 6 weeks
|
Safety Outcomes
|
6 weeks
|
Percentage of participants with symptomatic hypotension from baseline to Week 12
Time Frame: 12 weeks
|
Safety Outcomes
|
12 weeks
|
Percentage of participants with symptomatic hypotension from baseline to Week 6
Time Frame: 6 weeks
|
Safety Outcomes
|
6 weeks
|
Percentage of participants with serum sodium concentration below 135 mmol/l at Week 12
Time Frame: 12 weeks
|
Safety Outcomes
|
12 weeks
|
Percentage of participants with serum sodium concentration below 135 mmol/l at Week 6
Time Frame: 6 weeks
|
Safety Outcomes
|
6 weeks
|
Percentage of participants with serum sodium concentration above 145 mmol/l at Week 12
Time Frame: 12 weeks
|
Safety Outcomes
|
12 weeks
|
Percentage of participants with serum sodium concentration above 145 mmol/l at Week 6
Time Frame: 6 weeks
|
Safety Outcomes
|
6 weeks
|
Percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 12
Time Frame: 12 weeks
|
Safety Outcomes
|
12 weeks
|
Percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 6
Time Frame: 6 weeks
|
Safety Outcomes
|
6 weeks
|
Percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 12
Time Frame: 12 weeks
|
Safety Outcomes
|
12 weeks
|
Percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 6
Time Frame: 6 weeks
|
Safety Outcomes
|
6 weeks
|
Percentage of participants with eGFR drop of over 30% from baseline to Week 12
Time Frame: 12 weeks
|
Safety Outcomes
|
12 weeks
|
Percentage of participants with eGFR drop of over 30% from baseline to Week 6
Time Frame: 6 weeks
|
Safety Outcomes
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anthony Rodgers, Professor, The George Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Sodium Chloride Symporter Inhibitors
- Amlodipine
- Telmisartan
- Indapamide
Other Study ID Numbers
- GMRx2-HTN-2020-ACT1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
Clinical Trials on Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
-
George Medicines PTY LimitedCompletedHypertensionAustralia, United States, Nigeria, Sri Lanka, United Kingdom
-
Servier RussiaNot yet recruiting
-
Boehringer IngelheimCompletedHypertensionUnited States, Argentina, Brazil, Mexico, South Africa
-
Darnitsa Pharmaceutical CompanyInternational Pharmaceutical Research CenterCompleted
-
Yuhan CorporationCompleted
-
Darnitsa Pharmaceutical CompanyInternational Pharmaceutical Research CenterCompleted
-
Novartis PharmaceuticalsCompletedEssential HypertensionJapan
-
NovartisCompleted
-
Jeil Pharmaceutical Co., Ltd.CompletedDyslipidemia With HypertensionKorea, Republic of